Exhibit 99.1
Unaudited Condensed Combined Financial Statements
Page | ||||
F-2 | ||||
F-3 | ||||
F-4 | ||||
Unaudited Condensed Combined Balance Sheets as of March 29, 2020 and December 31, 2019 | F-5 | |||
F-6 | ||||
F-7 | ||||
F-8 |
F-1
Independent Auditors’ Review Report
The Board of Directors of Pfizer Inc.:
Report on the Financial Statements
We have reviewed the condensed combined financial statements of Upjohn (abusiness unit of Pfizer Inc.), which comprise the condensed combined balance sheet as of March 29, 2020, and the related condensed combined statements of income, comprehensive income, equity, and cash flows for thethree-month periods ended March 29, 2020 and March 31, 2019.
Management’s Responsibility
The Company’s management is responsible for the preparation and fair presentation of the condensed financial information in accordance with U.S. generally accepted accounting principles; this responsibility includes the design, implementation, and maintenance of internal control sufficient to provide a reasonable basis for the preparation and fair presentation of interim financial information in accordance with U.S. generally accepted accounting principles.
Auditors’ Responsibility
Our responsibility is to conduct our reviews in accordance with auditing standards generally accepted in the United States of America applicable to reviews of interim financial information and in accordance with the auditing standards of the Public Company Accounting Oversight Board (United States) (PCAOB). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States of America and in accordance with the auditing standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial information. Accordingly, we do not express such an opinion.
Conclusion
Based on our reviews, we are not aware of any material modifications that should be made to the condensed combined financial information referred to above for it to be in accordance with U.S. generally accepted accounting principles.
Report on Condensed Balance Sheet as of December 31, 2019
We have previously audited, in accordance with auditing standards generally accepted in the United States of America and in accordance with the auditing standards of the PCAOB, the combined balance sheet as of December 31, 2019, and the related combined statements of income, comprehensive income, equity, and cash flows for the year then ended (presented elsewhere in this document); and we expressed an unqualified audit opinion on those audited combined financial statements in our report dated March 20, 2020. In our opinion, the accompanying condensed combined balance sheet of Upjohn as of December 31, 2019 is consistent, in all material respects, with the audited combined financial statements from which it has been derived.
/s/ KPMG LLP
New York, New York
June 12, 2020
F-2
UPJOHN
(A Business Unit of Pfizer Inc.)
CONDENSED COMBINED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Revenues | $ | 1,861 | $ | 3,071 | ||||
Costs and expenses: | ||||||||
Cost of sales(a) | 400 | 398 | ||||||
Selling, informational and administrative expenses(a) | 413 | 535 | ||||||
Research and development expenses(a) | 60 | 62 | ||||||
Amortization of intangible assets | 36 | 39 | ||||||
Restructuring charges | 15 | 9 | ||||||
Other (income)/deductions––net | 51 | 37 | ||||||
|
|
|
| |||||
Income before provision for taxes on income | 885 | 1,991 | ||||||
Provision for taxes on income | 103 | 255 | ||||||
|
|
|
| |||||
Net income before allocation to noncontrolling interests | 782 | 1,736 | ||||||
Less: Net income/(loss) attributable to noncontrolling interests | (1 | ) | 1 | |||||
|
|
|
| |||||
Net income attributable to Upjohn | $ | 783 | $ | 1,735 | ||||
|
|
|
|
(a) | Excludes amortization of intangible assets. |
Amounts may not add due to rounding.
See Notes to Unaudited Condensed Combined Financial Statements, which are an integral part of these statements.
F-3
UPJOHN
(A Business Unit of Pfizer Inc.)
CONDENSED COMBINED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Net income before allocation to noncontrolling interests | $ | 782 | $ | 1,736 | ||||
|
|
|
| |||||
Foreign currency translation adjustments | (39 | ) | 46 | |||||
|
|
|
| |||||
Benefit plans: actuarial gains/(losses), net | (86 | ) | — | |||||
Reclassification adjustments related to amortization | 4 | 3 | ||||||
Reclassification adjustments related to settlements | 14 | — | ||||||
Other | 3 | (4 | ) | |||||
|
|
|
| |||||
(65 | ) | (1 | ) | |||||
|
|
|
| |||||
Benefit plans: prior service (costs)/credits and other, net | — | — | ||||||
Reclassification adjustments related to amortization | (5 | ) | (6 | ) | ||||
Other | (1 | ) | 1 | |||||
|
|
|
| |||||
(5 | ) | (5 | ) | |||||
|
|
|
| |||||
Other comprehensive income/(loss), before tax | (109 | ) | 39 | |||||
Tax provision/(benefit) on other comprehensive income/(loss)(a) | (2 | ) | (1 | ) | ||||
|
|
|
| |||||
Other comprehensive income/(loss) before allocation to noncontrolling interests | (107 | ) | 40 | |||||
|
|
|
| |||||
Comprehensive income before allocation to noncontrolling interests | 675 | 1,776 | ||||||
Less: Comprehensive income/(loss) attributable to noncontrolling interests | (1 | ) | — | |||||
|
|
|
| |||||
Comprehensive income attributable to Upjohn | $ | 676 | $ | 1,776 | ||||
|
|
|
|
(a) | SeeNote 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss). |
Amounts may not add due to rounding.
See Notes to Unaudited Condensed Combined Financial Statements, which are an integral part of these statements.
F-4
UPJOHN
(A Business Unit of Pfizer Inc.)
CONDENSED COMBINED BALANCE SHEETS
(millions of dollars) | March 29, 2020 | December 31, 2019 | ||||||
(Unaudited) | ||||||||
Assets | ||||||||
Cash and cash equivalents | $ | 191 | $ | 184 | ||||
Trade accounts receivable, less allowance for doubtful accounts: 2020—$32; 2019—$40 | 2,029 | 1,946 | ||||||
Inventories | 1,111 | 1,155 | ||||||
Current tax assets | 446 | 628 | ||||||
Other current assets | 278 | 261 | ||||||
|
|
|
| |||||
Total current assets | 4,055 | 4,173 | ||||||
Property, plant and equipment, less accumulated depreciation: 2020—$1,819; 2019—$1,796 | 1,003 | 999 | ||||||
Identifiable intangible assets, less accumulated amortization | 1,403 | 1,434 | ||||||
Goodwill | 8,695 | 8,709 | ||||||
Noncurrent deferred tax assets and other noncurrent tax assets | 624 | 651 | ||||||
Other noncurrent assets | 407 | 399 | ||||||
|
|
|
| |||||
Total assets | $ | 16,187 | $ | 16,366 | ||||
|
|
|
| |||||
Liabilities and Equity | ||||||||
Trade accounts payable | $ | 453 | $ | 426 | ||||
Income taxes payable | 389 | 371 | ||||||
Accrued compensation and related items | 306 | 335 | ||||||
Other current liabilities | 1,966 | 2,125 | ||||||
|
|
|
| |||||
Total current liabilities | 3,114 | 3,257 | ||||||
Pension benefit obligations, net | 387 | 306 | ||||||
Postretirement benefit obligations, net | 197 | 198 | ||||||
Noncurrent deferred tax liabilities | 34 | 38 | ||||||
Other taxes payable | 4,636 | 4,623 | ||||||
Other noncurrent liabilities | 420 | 426 | ||||||
|
|
|
| |||||
Total liabilities | 8,788 | 8,849 | ||||||
|
|
|
| |||||
Commitments and Contingencies | ||||||||
Business unit equity | 8,213 | 8,224 | ||||||
Accumulated other comprehensive loss | (814 | ) | (707 | ) | ||||
|
|
|
| |||||
Total equity | 7,398 | 7,517 | ||||||
|
|
|
| |||||
Total liabilities and equity | $ | 16,187 | $ | 16,366 | ||||
|
|
|
|
Amounts may not add due to rounding.
See Notes to Unaudited Condensed Combined Financial Statements, which are an integral part of these statements.
F-5
UPJOHN
(A Business Unit of Pfizer Inc.)
CONDENSED COMBINED STATEMENTS OF EQUITY
(UNAUDITED)
Upjohn | ||||||||||||||||||||
(millions of dollars) | Business Unit Equity | Accumulated Other Comp. Income/(Loss) | Total Business Unit Equity | Equity Attributable to Noncontrolling Interests | Total Equity | |||||||||||||||
Balance, December 31, 2019 | $ | 8,224 | $ | (707 | ) | $ | 7,517 | $ | — | $ | 7,517 | |||||||||
Net income/(loss) | 783 | 783 | (1 | ) | 782 | |||||||||||||||
Other comprehensive income/(loss), | (107 | ) | (107 | ) | — | (107 | ) | |||||||||||||
Share-based payment transactions | 12 | 12 | 12 | |||||||||||||||||
Net transfers between Pfizer and noncontrolling interests | 1 | 1 | ||||||||||||||||||
Net transfers––Pfizer(a) | (807 | ) | (807 | ) | (807 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Balance, March 29, 2020 | $ | 8,213 | $ | (814 | ) | $ | 7,398 | $ | — | $ | 7,398 | |||||||||
|
|
|
|
|
|
|
|
|
|
Upjohn | ||||||||||||||||||||
(millions of dollars) | Business Unit Equity | Accumulated Other Comp. Income/(Loss) | Total Business Unit Equity | Equity Attributable to Noncontrolling Interests | Total Equity | |||||||||||||||
Balance, December 31, 2018 | $ | 7,653 | $ | (660 | ) | $ | 6,992 | $ | — | $ | 6,992 | |||||||||
Net income | 1,735 | 1,735 | 1 | 1,736 | ||||||||||||||||
Other comprehensive income/(loss), | 41 | 41 | (1 | ) | 40 | |||||||||||||||
Share-based payment transactions | 22 | 22 | 22 | |||||||||||||||||
Net transfers between Pfizer and noncontrolling interests | — | — | ||||||||||||||||||
Net transfers––Pfizer(a) | (1,359 | ) | (1,359 | ) | (1,359 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Balance, March 31, 2019 | $ | 8,051 | $ | (620 | ) | $ | 7,431 | $ | — | $ | 7,431 | |||||||||
|
|
|
|
|
|
|
|
|
|
(a) | SeeNote 15 for the major components ofNet transfers—Pfizer. |
Amounts may not add due to rounding.
See Notes to Unaudited Condensed Combined Financial Statements, which are an integral part of these statements.
F-6
UPJOHN
(A Business Unit of Pfizer Inc.)
CONDENSED COMBINED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Operating Activities | ||||||||
Net income before allocation to noncontrolling interests | $ | 782 | $ | 1,736 | ||||
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 77 | 83 | ||||||
Tax Cuts and Jobs Act (TCJA) impact(a) | — | (28 | ) | |||||
Deferred taxes | 29 | 23 | ||||||
Share-based compensation expense | 12 | 22 | ||||||
Benefit plan contributions in excess of expense/income | (2 | ) | (11 | ) | ||||
Other adjustments, net | 1 | (22 | ) | |||||
Other changes in assets and liabilities | (40 | ) | (417 | ) | ||||
|
|
|
| |||||
Net cash provided by operating activities | 859 | 1,386 | ||||||
|
|
|
| |||||
Investing Activities | ||||||||
Purchases of property, plant and equipment | (14 | ) | (10 | ) | ||||
Acquisitions of intangible assets | (5 | ) | — | |||||
Other investing activities, net | — | — | ||||||
|
|
|
| |||||
Net cash used in investing activities | (19 | ) | (9 | ) | ||||
|
|
|
| |||||
Financing Activities | ||||||||
Net financing activities with Pfizer | (831 | ) | (1,361 | ) | ||||
|
|
|
| |||||
Net cash used in financing activities | (831 | ) | (1,361 | ) | ||||
|
|
|
| |||||
Effect of exchange-rate changes on cash and cash equivalents | (2 | ) | — | |||||
|
|
|
| |||||
Net increase in cash and cash equivalents | 7 | 16 | ||||||
Cash and cash equivalents, beginning | 184 | — | ||||||
|
|
|
| |||||
Cash and cash equivalents, end | $ | 191 | $ | 16 | ||||
|
|
|
| |||||
Supplemental Cash Flow Information | ||||||||
Cash paid during the period for: | ||||||||
Income taxes | $ | 64 | $ | 238 | ||||
Interest | — | — |
(a) | As a result of the enactment of the Tax Cuts and Jobs Act (TCJA) in December 2017,Provision for taxes on income for the three months ended March 31, 2019 was favorably impacted by approximately $28 million, primarily as a result of additional guidance issued by the U.S. Department of Treasury. |
Amounts may not add due to rounding.
See Notes to Unaudited Condensed Combined Financial Statements, which are an integral part of these statements.
F-7
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Note 1. Business Description and Basis of Presentation
A. Business Description
Upjohn (collectively, Upjohn, the Upjohn Business, the business, the company, we, us and our) is a business unit of Pfizer Inc. (Pfizer). We are a China-based global pharmaceutical company with a portfolio of well-established, primarilyoff-patent branded and generic medicines, includingLyrica,Lipitor,Norvasc,Celebrexand Viagra, as well as a U.S.-based generics platform, Greenstone. Our pharmaceutical products are used to treatnon-communicable diseases (NCDs). We commercialize, manufacture and develop pharmaceutical products across a broad range of therapeutic areas, including cardiovascular, pain and neurology, psychiatry, urology and ophthalmology. The accompanying condensed combined financial statements include the accounts of all operations that comprise the Upjohn operations of Pfizer.
On January 23, 2020, Upjohn China entered into a definitive agreement to acquire Shanghai Minghui Pharmaceutical Co., Ltd. (Minghui) from Shanghai Pharmaceutical Co., Ltd., which is a state-owned enterprise in China. After the completion of a listing and bidding process, Upjohn agreed to acquire Minghui for 40 million renminbi (RMB) (approximately $5 million, net of cash acquired of approximately $1 million). In February 2020, Upjohn remitted the total purchase price to SUAEE, the institution managing the listing and bidding process. The closing conditions provided in the transaction documents have been met. Minghui obtained a new business license in April 2020 under which Upjohn Hong Kong is registered as the sole shareholder of Minghui. Minghui’s drug distribution license and good supply practices certification in China have also been updated to reflect such change in ownership. The acquisition of Minghui was accounted for by Upjohn as the acquisition of a group of assets rather than the acquisition of a business. In connection with this asset acquisition, we recorded $5 million inIdentifiable intangible assets, consisting of a licensing agreement—seeNote 9A.
On July 29, 2019, Pfizer announced it had entered into a definitive agreement to combine Upjohn with Mylan N.V. (Mylan), creating a new global pharmaceutical company. The name of the new company to be formed by the planned combination of the Upjohn Business and Mylan will be “Viatris.” Under the terms of the agreement, which is structured as anall-stock, Reverse Morris Trust transaction, Pfizer will contribute the Upjohn Business to its wholly-owned subsidiary, Upjohn Inc. (Newco) and distribute its ownership interest in Newco to Pfizer shareholders via either aspin-off or asplit-off (the Distribution). Pfizer intends to effect the Distribution by way of aspin-off. Newco will issue $12 billion of debt in connection with its separation from Pfizer, and, at or prior to the Distribution, Newco will make a cash payment to Pfizer equal to $12 billion as partial consideration for the contribution of the Upjohn Business from Pfizer to Newco. Immediately after the Distribution, Newco will be combined with Mylan. Pfizer shareholders would own 57% of the combined new company and former Mylan shareholders would own 43% on a fully diluted basis. The transaction is generally expected to be tax free to Pfizer and Pfizer shareholders and is expected to close in the fourth quarter of 2020, subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals.
Pfizer, the Upjohn Business and Mylan are in the process of negotiating the terms on which Pfizer would transfer its Meridian Medical Technologies business (Meridian), the manufacturer of EpiPen® and other auto-injector products, and/or certain Pfizer assets that currently form part of apre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan collaboration) to Viatris following the completion of the proposed combination of the Upjohn Business and Mylan. There can be no assurance that any agreement or transaction will result from these negotiations and if the parties are unsuccessful in their efforts to negotiate the terms of such potential transactions, Meridian and/or the Pfizer assets that currently form part of the Mylan-Japan collaboration will remain with Pfizer. The Upjohn Business’s results of operations, financial condition and cash flows presented in these condensed combined financial statements and notes thereto do not include the results of operations, assets and liabilities or cash flows of Meridian and the Mylan-Japan collaboration.
F-8
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
B. Basis of Presentation
We prepared the accompanying condensed combined financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.
The financial information included in our condensed combined financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 23, 2020 and February 24, 2019. The financial information included in our condensed combined financial statements for U.S. subsidiaries is as of and for the three months ended March 29, 2020 and March 31, 2019. All significant intercompany balances and transactions among the legal entities that comprise Upjohn have been eliminated. Balances due from or due to Pfizer that are expected to be cash-settled, if any, are included, depending on the nature of the balance, inOther current assets, Other noncurrent assets,Other current liabilities andOther noncurrent liabilities on the condensed combined balance sheets. All balances and transactions among Upjohn and Pfizer that are not cash-settled are shown as part ofBusiness unit equity on the condensed combined balance sheets and represent the net of amounts settled without payment (to)/from Pfizer. For additional information about balances and transactions among Upjohn and Pfizer, seeNote 15.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited condensed combined financial statements included in this document. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in these interim financial statements should be read in conjunction with the combined financial statements and accompanying notes for the year ended December 31, 2019 included elsewhere in this document.
Certain amounts in the condensed combined financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
As of January 1, 2020, we adopted four new accounting standards. SeeNote 2A for further information.
The condensed combined financial statements have been derived from the consolidated financial statements and accounting records of Pfizer and include allocations for direct costs and indirect costs attributable to the operations of the Upjohn Business of Pfizer. As part of a Pfizer reorganization beginning in 2019, Upjohn was positioned as a standalone division within Pfizer with distinct and dedicated manufacturing, marketing and other commercial activities, research, development, medical, regulatory and limited enabling functions. As a result, many of the costs for certain support functions that, prior to 2019, were provided to Upjohn on a centralized basis within Pfizer are, beginning in 2019, incurred directly by Upjohn.
These condensed combined financial statements do not purport to reflect what the results of operations, comprehensive income, financial position, equity or cash flows would have been had we operated as an independent standalone company during the periods presented.
• | The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 include limited costs directly incurred by Upjohn for certain support functions (Enabling Functions) and allocations to Upjohn for Enabling Functions that are provided on a centralized basis within Pfizer, such as expenses for business technology, facilities, legal, finance, human resources, insurance, public affairs and procurement, among others. Allocations are based on either a specific identification basis or, when specific identification is not practicable, proportional |
F-9
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
allocation methods (e.g., using third-party sales, headcount, etc.), depending on the nature of the services. |
• | The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 include certain manufacturing and supply costs directly incurred by the Upjohn Global Supply network for manufacturing facilities, external supply, and logistics and support as well as allocations of such costs incurred by manufacturing plants that are shared with other Pfizer business units and centralized Pfizer Global Supply (PGS) costs that Pfizer did not routinely allocate to its business units. These costs may include manufacturing variances and changes in the standard costs of inventory, among others. Where used, allocations are based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods, such as Upjohn identified manufacturing costs, depending on the nature of the costs. |
• | The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 include directly incurred costs for certain Upjohn research and development (R&D) activities and allocations of certain research, development and medical (RDM) expenses managed by Pfizer’s R&D organization. Pfizer does not routinely allocate these costs to any of its business units. These allocations are based on either a specific identification basis or, when specific identification is not practicable, our estimates of the costs incurred in connection with the R&D activities associated with Upjohn. |
• | The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 also include allocations from Enabling Functions and PGS for restructuring charges and additional depreciation associated with asset restructuring and implementation costs. Pfizer does not routinely allocate these costs to any of its business units. For additional information about allocations of restructuring charges and other costs associated with cost-reduction/productivity initiatives, seeNote 3. |
• | The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 include allocations of pension and postretirement service costs that have been deemed attributable to Upjohn operations. For information about allocations of pension and postretirement costs, seeNote 12. |
• | The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 include allocations of other corporate and commercial costs, which can include, but are not limited to, certain compensation items, such as share-based compensation expense and certain fringe benefit expenses maintained on a centralized basis within Pfizer, as well as Pfizer hedging activity on intercompany inventory. Pfizer does not routinely allocate these costs to any of its business units. The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 also include a combination of allocations to Upjohn and directly incurred costs for other corporate and commercial costs for certain strategy, business development, portfolio management and valuation capabilities. Allocations are based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods (e.g., using third-party sales, headcount, etc.), depending on the nature of the services. |
• | The condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 include allocations of purchase accounting impacts resulting from business combinations. These impacts are primarily associated with the Upjohn related assets acquired as part of Pfizer’s acquisitions of Pharmacia in 2003 and Wyeth in 2009, and primarily include amortization related to the increase in fair value of the acquired finite-lived intangible assets. |
• | The condensed combined balance sheets at March 29, 2020 and December 31, 2019 reflect all of the assets and liabilities of Pfizer that are either specifically identifiable or are directly attributable to |
F-10
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Upjohn and its operations. Cash from Upjohn operations in subsidiaries that are not completely Upjohn dedicated is not included in the condensed combined balance sheets since this cash is swept into Pfizer’s centralized cash management system. We participate in Pfizer’s centralized cash management system and generally all excess cash is transferred to Pfizer on a daily basis. Cash disbursements for operations and/or investing activities are funded as needed by Pfizer. Accordingly, the Upjohn cash balance at March 29, 2020 and December 31, 2019 is not representative of an independent company and could be significantly different at another point in time. |
• | For benefit plans, the condensed combined balance sheets at March 29, 2020 and December 31, 2019 only include the assets and liabilities of benefit plans sponsored by Upjohn—seeNote 12. |
• | The condensed combined financial statements do not include allocations of Pfizer corporate debt as none is specifically related to our operations. The condensed combined statements of income include an allocation of Pfizer interest-related expenses, including the effect of hedging activities associated with the Pfizer corporate debt and an allocation for interest income associated with the Pfizer corporate investments—seeNote 4.We participate in Pfizer’s centralized hedging and offsetting programs. As such, in the condensed combined statements of income, we include the impact of Pfizer’s derivative financial instruments used for offsetting changes in foreign currency rates net of the related exchange gains and losses for the portion that is deemed to be associated with Upjohn operations. |
Management believes that the allocations are a reasonable reflection of the services received or the costs incurred on behalf of Upjohn and its operations and that the condensed combined statements of income reflect all costs of the Upjohn Business of Pfizer.
The allocated expenses from Pfizer primarily include:
• | Enabling functions operating expenses—approximately $117 million for the three months ended March 29, 2020 and $176 million for the three months ended March 31, 2019 ($2 million and $0.2 million income inCost of sales; $108 million and $175 million inSelling, informational and administrative expenses; and $7 million and $0.9 million inResearch and development expenses). |
• | PGS manufacturing costs—approximately $31 million for the three months ended March 29, 2020 and $3 million for the three months ended March 31, 2019 ($31 million and $3 million inCost of sales; $0.4 million and $0.1 million inSelling, informational and administrative expenses;and $0.1 million and $0.1 million inResearch and development expenses). |
• | Research, development and medical expenses—approximately $2 million for the three months ended March 29, 2020 and the three months ended March 31, 2019 ($0.1 million income and negligible inCost of sales; $1 million and $2 million inSelling, informational and administrative expenses; and $0.3 million and $0.3 million inResearch and development expenses). |
• | Restructuring charges/(credits)—approximately $2 million income for the three months ended March 29, 2020 and $2 million for the three months ended March 31, 2019 (all included inRestructuring charges). |
• | Other costs associated with cost-reduction/productivity initiatives—additional depreciation associated with asset restructuring—negligible for the three months ended March 29, 2020 and approximately $1 million for the three months ended March 31, 2019 ($0.5 million inCost of sales;negligible amounts inSelling, informational and administrative expenses;and $0.7 million inResearch and development expenses). |
• | Other costs associated with cost-reduction/productivity initiatives—implementation costs—approximately $3 million for the three months ended March 29, 2020 and $5 million for the three months ended March 31, 2019 ($2 million and $3 million inCost of sales; $0.9 million and $2 million |
F-11
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
inSelling, informational and administrative expenses;and $0.1 million income and $0.2 million inResearch and development expenses). |
• | Fringe benefit expenses—approximately $1 million income for the three months ended March 29, 2020 and $4 million for the three months ended March 31, 2019 ($0.1 million income and $0.5 million inCost of sales; $1 million income and $4 million inSelling, informational and administrative expenses; and negligible amounts in both periods inResearch and development expenses). |
• | Share-based compensation expense—approximately $12 million for the three months ended March 29, 2020 and $22 million for the three months ended March 31, 2019 ($2 million and $2 million inCost of sales; $11 million and $17 million inSelling, informational and administrative expenses; and $0.3 million income and $3 million inResearch and development expenses). |
• | Other(income)/deductions-net—approximately $62 million for the three months ended March 29, 2020 and $37 million for the three months ended March 31, 2019. Amounts primarily include an allocation of net interest expense of approximately $54 million for the three months ended March 29, 2020 and $79 million for the three months ended March 31, 2019, reflecting an allocation for interest-related expenses, including the effect of hedging activities, associated with the Pfizer corporate debt and an allocation for interest income associated with the Pfizer corporate investments. In the three months ended March 31, 2019, the amount also includes, among other things, an allocation of income from insurance recoveries of $15 million related to the hurricanes in Puerto Rico toward the end of the third quarter of 2017—seeNote 4. |
• | Other corporate and commercial costs—approximately $3 million for the three months ended March 29, 2020 and $2 million for the three months ended March 31, 2019 ($7 million income and $6 million income inCost of sales; $9 million and $6 million inSelling, informational and administrative expenses; and $0.8 million and $2 million inResearch and development expenses). |
The income tax provision/(benefit) in the condensed combined statements of income for the three months ended March 29, 2020 and March 31, 2019 has been calculated as if Upjohn filed a tax return separate from Pfizer in the various jurisdictions where it does business.
Note 2. Significant Accounting Policies
A. Adoption of New Accounting Standards
On January 1, 2020, we adopted four new accounting standards.
Credit Losses on Financial Instruments—We adopted a new accounting standard for credit losses on financial instruments, which replaces the probable initial recognition threshold for incurred loss estimates under prior guidance with a methodology that reflects expected credit loss estimates. The standard generally impacts financial assets that have a contractual right to receive cash and are not accounted for at fair value through net income, such as accounts receivable andheld-to-maturity debt securities. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for certain financial instruments, using information such as historical experience, current economic conditions and information, and the use of reasonable and supportable forecasted information. The standard also amends existing impairment guidance foravailable-for-sale debt securities to incorporate a credit loss allowance and allows for reversals of credit impairments in the event the issuer’s credit improves.
We adopted the new accounting standard utilizing the modified retrospective method, and therefore, no adjustments were made to amounts in our prior period financial statements. The cumulative effect of adopting the standard as an adjustment to the opening balance ofBusiness unit equity was not material. The impact of adoption did not have a material impact on our condensed combined statement of income or condensed combined statement of cash flows for the three months ended March 29, 2020, nor on our condensed combined balance sheet as of March 29, 2020. For additional information, seeNote 2B.
F-12
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Goodwill Impairment Testing—We prospectively adopted the new accounting standard, which eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value. There was no impact to our condensed combined financial statements from the adoption of this new standard.
Implementation Costs in a Cloud Computing Arrangement—We prospectively adopted the new accounting standard related to customers’ accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs incurred to develop or obtaininternal-use software. There was no material impact to our condensed combined financial statements from the adoption of this new standard.
Collaboration Agreements—We prospectively adopted the new accounting standard, which provides new guidance clarifying the interaction between the accounting for collaborative arrangements and revenue from contracts with customers. There was no impact to our condensed combined financial statements from the adoption of this new standard.
On January 1, 2019, we adopted a new accounting standard for lease accounting. For additional information, see Notes to Combined Financial Statements—Note 3A. Significant Accounting Policies: Adoption of New Accounting Standardincluded in our combined financial statements and accompanying notes for the year ended December 31, 2019 included elsewhere in this document.
B. Revenues and Trade Accounts Receivable
Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $1.4 billion as of March 29, 2020 and $1.6 billion as of December 31, 2019.
The following table provides information about the balance sheet classification of these accruals:
(millions of dollars) | March 29, 2020 | December 31, 2019 | ||||||
Reserve againstTrade accounts receivable, less allowance for doubtful accounts | $ | 396 | $ | 435 | ||||
Other current liabilities: | ||||||||
Rebate accruals(a) | 609 | 737 | ||||||
Other accruals | 215 | 224 | ||||||
Other noncurrent liabilities | 216 | 217 | ||||||
|
|
|
| |||||
Total accrued rebates and other accruals | $ | 1,435 | $ | 1,614 | ||||
|
|
|
|
(a) | The decrease in rebate accruals reflects the loss of exclusivity of Lyrica in the United States, with multi-source generic competition beginning in July 2019. |
Trade Accounts Receivable—Trade accounts receivableare stated at their net realizable value. The allowance for credit losses against gross trade accounts receivable reflects the best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versusnon-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and
F-13
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
During the first quarter of 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed combined financial statements.
Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
Note 3. Restructuring Charges/(Credits) and Other Costs Associated with Cost-Reduction/Productivity Initiatives
The condensed combined statements of income include costs associated with Pfizer’s cost-reduction/productivity initiatives. The expenses include direct costs and charges as well as an allocation of indirect costs and charges that have been deemed attributable to Upjohn. The condensed combined balance sheets reflect the accrued restructuring charges directly attributable to the Upjohn operations. In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All operating functions may be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as groups such as worldwide technology, shared services and corporate operations.
2017-2019 Initiatives and Organizing for Growth
During 2018, Pfizer reviewed its business operations and determined that, at the start of its 2019 fiscal year, Pfizer would begin operating under a new commercial structure, which reorganized Pfizer operations into three businesses –Biopharma, a science-based innovative medicines business; Upjohn; and a Consumer Healthcare business. As part of a Pfizer reorganization beginning in 2019, Upjohn was positioned as a standalone division within Pfizer with distinct and dedicated manufacturing, marketing and other commercial activities, research, development, medical, regulatory and limited enabling functions, which better enables us to optimize our growth potential. Beginning in the fourth quarter of 2018, Pfizer reviewed previously planned initiatives and new initiatives and combined the 2017-2019 initiatives with its Organizing for Growth initiatives to form one cohesive plan. Initiatives for the combined program include activities related to the optimization of the Pfizer manufacturing plant network, the centralization of Pfizer corporate and platform functions, and the simplification and optimization of the operating business structure and functions that support them.
Through March 29, 2020, we have incurred cumulative direct restructuring charges (primarily related to employee termination costs) and implementation costs associated with the combined program of 2017-2019 initiatives and Organizing for Growth initiatives of approximately $159 million. In the first three months of 2020, we incurred total direct restructuring charges and implementation costs of $18 million. We expect to incur approximately $8 million of additional direct, mostly cash, restructuring charges and implementation costs primarily over the remainder of 2020 and into 2021 to complete activities associated with the combined program of cost-reduction initiatives.
F-14
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Current-Period Key Activities
The components of costs incurred in connection with the Pfizer cost-reduction/productivity initiatives described above follow:
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Restructuring Charges/(Credits): | ||||||||
Total restructuring charges—direct:(a) | ||||||||
Employee termination costs | $ | 17 | $ | 7 | ||||
Asset impairment charges | — | — | ||||||
Exit costs | — | — | ||||||
|
|
|
| |||||
Total restructuring charges—direct | 17 | 7 | ||||||
|
|
|
| |||||
Restructuring charges/(credits)—allocated:(a) | ||||||||
Employee termination costs/(credits) | (2 | ) | 2 | |||||
Asset impairment charges | — | — | ||||||
Exit costs | — | — | ||||||
|
|
|
| |||||
Total restructuring charges/(credits)—allocated | (2 | ) | 2 | |||||
|
|
|
| |||||
Total restructuring charges | 15 | 9 | ||||||
|
|
|
| |||||
Other Costs/(Credits) Associated with Cost-Reduction/Productivity Initiatives: | ||||||||
Additional depreciation associated with asset restructuring—allocated(b) | — | 1 | ||||||
Implementation costs/(credits)—direct(c) | 1 | (1 | ) | |||||
Implementation costs—allocated(c) | 3 | 5 | ||||||
|
|
|
| |||||
Total costs associated with cost-reduction/productivity initiatives | $ | 19 | $ | 15 | ||||
|
|
|
|
(a) | In the first three months of 2020 and 2019, restructuring charges were primarily related to employee termination costs associated with cost-reduction and productivity initiatives. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. In the first three months of 2020, direct restructuring charges are primarily related to the Greater China segment (approximately $9 million) and Other (approximately $8 million). In the first three months of 2019, direct restructuring charges are primarily related to the Developed Markets segment (approximately $4 million), the Greater China segment (approximately $2 million) and the Emerging Markets segment (approximately $0.1 million). |
(b) | Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. In the first three months of 2019, the additional depreciation is primarily included inCost of sales ($0.5 million) andResearch and development expenses ($0.7 million). |
(c) | Implementation costs represent external, incremental costs directly related to implementing cost-reduction/productivity initiatives. Direct implementation costs/(credits) in the first three months of 2020 and 2019 are primarily included inCost of sales.In the first three months of 2020, allocated implementation costs are included inCost of sales($2 million),Selling, informational and administrative expenses($1 million) andResearch and development expenses ($0.1 million income). In the first three months of 2019, allocated implementation costs are included inCost of sales($3 million),Selling, informational and administrative expenses ($2 million) andResearch and development expenses ($0.2 million). |
F-15
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
The components and activity of our direct restructuring charges identified with Upjohn follow:
(millions of dollars) | Employee Termination Costs | Asset Impairments | Exit Costs | Accrual | ||||||||||||
Balance, December 31, 2019(a) | $ | 202 | $ | — | $ | 1 | $ | 202 | ||||||||
Provision | 17 | — | — | 17 | ||||||||||||
Utilization and other(b) | (74 | ) | — | — | (75 | ) | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Balance, March 29, 2020(c) | $ | 144 | $ | — | $ | 1 | $ | 145 | ||||||||
|
|
|
|
|
|
|
|
(a) | Included inOther current liabilities($153 million) andOther noncurrent liabilities($49 million). |
(b) | Includes adjustments for foreign currency translation. |
(c) | Included inOther current liabilities($95 million) andOther noncurrent liabilities($49 million). |
Note 4. Other (Income)/Deductions—Net
The following table provides components ofOther (income)/deductions—net:
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Certain legal matters, net(a) | $ | 1 | $ | 4 | ||||
Net periodic benefit costs/(credits) other than service costs(b) | 6 | (7 | ) | |||||
Other, net(c) | (18 | ) | 2 | |||||
|
|
|
| |||||
Other (income)/deductions—net—direct | (11 | ) | (1 | ) | ||||
|
|
|
| |||||
Net interest expense—allocated(d) | 54 | 79 | ||||||
Other, net—allocated(e) | 9 | (41 | ) | |||||
|
|
|
| |||||
Other (income)/deductions—net—allocated | 62 | 37 | ||||||
|
|
|
| |||||
Other (income)/deductions—net | $ | 51 | $ | 37 | ||||
|
|
|
|
(a) | In the first three months of 2020, represents a legal reserve for a pending matter. In the first three months of 2019, represents legal reserves for certain pending matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. For additional information, seeNote 13A. |
(b) | In the first three months of 2020, includes, among other things, a settlement charge of $14 million related to lump sum payouts to certain terminated plan participants in our pension plan in Puerto Rico. For additional information, seeNote 12. |
(c) | In the first three months of 2020, includes, among other items, $12 million of rental income associated with related party leasing arrangements in Singapore entered into with Pfizer on May 27, 2019 (for additional information, seeNote 15) and $6 million of income from government refunds in China. In the first three months of 2019, includes, among other items, $4 million of costs associated with certain initiatives in international jurisdictions and $4 million of income from government refunds in China. |
(d) | Represents an allocation of interest expense associated with the Pfizer corporate debt and an allocation of interest income associated with the Pfizer corporate investments. Allocated capitalized interest expense totaled $4 million in the first three months of 2020 and $6 million in the first three months of 2019. |
F-16
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
(e) | Represents allocation of miscellaneous other income and deductions. In the first three months of 2020, among other items, includes an allocation of net currency exchange losses and net losses associated with Pfizer’s investments, partially offset by an allocation of net gains associated with Pfizer’s hedging activities. In the first three months of 2019, among other items, includes an allocation of net currency exchange gains and net gains associated with Pfizer’s investments, partially offset by an allocation of net losses associated with Pfizer’s hedging activities. The first three months of 2019 also includes an allocation of income from insurance recoveries of $15 million related to the hurricanes in Puerto Rico toward the end of the third quarter of 2017. |
Note 5. Tax Matters
A. Taxes on Income
During the periods presented in the condensed combined financial statements, Upjohn did not generally file separate tax returns, as Upjohn was generally included in the tax grouping of other Pfizer entities within the respective entity’s tax jurisdiction. The income tax provision included in these condensed combined financial statements has been calculated using the separate return basis, as if Upjohn filed a separate tax return.
Our effective tax rate for income was 11.7% for the first three months of 2020, compared to 12.8% for the first three months of 2019.
The lower effective tax rate for the first three months of 2020 in comparison with the same period in 2019 was primarily due to:
• | the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; and |
• | an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years and the expirations of certain statutes of limitations, |
partially offset by
• | thenon-recurrence of the tax benefit of approximately $28 million recorded in the first three months of 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the enactment of the TCJA. |
Our estimated $4.3 billion repatriation liability on accumulated post-1986 foreign earnings as of December 31, 2019, for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026, is reported inIncometaxes payable($320 million) and the remaining liability is reported inOther taxes payable in our condensed combined balance sheet as of March 29, 2020. We expect to pay the second installment of $320 million in July 2020, which was originally due to be paid in April 2020 but was recently extended to July 2020 by the Internal Revenue Service (IRS) in response to the pandemic resulting from a novel disease caused by a strain of coronavirus(COVID-19). Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was signed into law in the U.S. to provide certain relief as a result of theCOVID-19 pandemic. In addition, governments around the world have enacted or implemented various forms of tax relief measures in response to the economic conditions in the wake ofCOVID-19. As of March 29, 2020, neither the CARES Act nor changes to income tax laws or regulations in other jurisdictions had a significant impact on our effective tax rate.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All our tax positions are subject to audit by the local
F-17
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments, and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2011-2015 are currently under audit. Tax years 2016-2020 are open but not under audit. All other tax years are closed.
In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Asia (2009-2020, primarily reflecting Japan, China and Singapore), Canada (2013-2020), Europe (2011-2020, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2020, primarily reflecting Brazil) and Puerto Rico (2015-2020).
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
The following table provides the components of theTax provision/(benefit) on other comprehensive income/(loss):
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Benefit plans: actuarial gains/(losses), net | $ | (3 | ) | $ | — | |||
Reclassification adjustments related to amortization | 1 | 1 | ||||||
Reclassification adjustments related to settlements | — | — | ||||||
Other | 1 | (1 | ) | |||||
|
|
|
| |||||
(1 | ) | — | ||||||
|
|
|
| |||||
Benefit plans: prior service (costs)/credits and other, net | — | — | ||||||
Reclassification adjustments related to amortization | (1 | ) | — | |||||
Other | — | — | ||||||
|
|
|
| |||||
(1 | ) | — | ||||||
|
|
|
| |||||
Tax provision/(benefit) on other comprehensive income/(loss) | $ | (2 | ) | $ | (1 | ) | ||
|
|
|
|
Note 6. Accumulated Other Comprehensive Income/(Loss)
The following table provides the changes, net of tax, inAccumulated other comprehensive lossfor the first three months of 2020:
Net Unrealized Gains/(Losses) | Benefit Plans | |||||||||||||||
(millions of dollars) | Foreign Currency Translation Adjustment | Actuarial Gains/ (Losses) | Prior Service (Costs)/Credits and Other | Accumulated Other Comprehensive Income/(Loss) | ||||||||||||
Balance, December 31, 2019 | $ | (341 | ) | $ | (424 | ) | $ | 59 | $ | (707 | ) | |||||
Other comprehensive income/(loss)(a) | (39 | ) | (64 | ) | (4 | ) | (107 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Balance, March 29, 2020 | $ | (380 | ) | $ | (489 | ) | $ | 55 | $ | (814 | ) | |||||
|
|
|
|
|
|
|
|
(a) | Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests, which were negligible in the first three months of 2020. |
F-18
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
The following table provides the changes, net of tax, inAccumulated other comprehensive lossfor the first three months of 2019:
Net Unrealized Gains/(Losses) | Benefit Plans | |||||||||||||||
(millions of dollars) | Foreign Currency Translation Adjustments | Actuarial Gains/ (Losses) | Prior Service (Costs)/Credits and Other | Accumulated Other Comprehensive Income/(Loss) | ||||||||||||
Balance, December 31, 2018 | $ | (330 | ) | $ | (429 | ) | $ | 99 | $ | (660 | ) | |||||
Other comprehensive income/(loss)(a) | 46 | (1 | ) | (5 | ) | 41 | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Balance, March 31, 2019 | $ | (283 | ) | $ | (430 | ) | $ | 94 | $ | (620 | ) | |||||
|
|
|
|
|
|
|
|
(a) | Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $0.6 million loss for the first three months of 2019. |
Note 7. Financial Instruments
The condensed combined balance sheets include the financial assets and liabilities that are directly attributable to Upjohn—see Note 1B.
Financial Assets and Liabilities
As of March 29, 2020 and December 31, 2019, financial assets and liabilities consist primarily of cash and cash equivalents, accounts receivable and accounts payable.
The recorded amounts for cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these instruments.
Note 8. Inventories
The condensed combined balance sheets include all of the inventory directly attributable to Upjohn.
The following table provides the components ofInventories:
(millions of dollars) | March 29, 2020 | December 31, 2019 | ||||||
Finished goods | $ | 360 | $ | 441 | ||||
Work-in-process | 652 | 593 | ||||||
Raw materials and supplies | 98 | 121 | ||||||
|
|
|
| |||||
Inventories | $ | 1,111 | $ | 1,155 | ||||
|
|
|
| |||||
Noncurrent inventories not included above(a) | $ | 78 | $ | 76 | ||||
|
|
|
|
(a) | Included inOther noncurrent assets—seeNote 10B. There are no recoverability issues associated with these amounts. |
Note 9. Identifiable Intangible Assets and Goodwill
The condensed combined balance sheets include all of the goodwill and identifiable intangible assets directly attributable to Upjohn. The condensed combined statements of income include all of the amortization expense associated with finite-lived identifiable intangible assets.
F-19
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
A. Identifiable Intangible Assets
Balance Sheet Information
The following table provides the components ofIdentifiable intangible assets:
March 29, 2020 | December 31, 2019 | |||||||||||||||||||||||
(millions of dollars) | Gross Carrying Amount | Accumulated Amortization | Identifiable Intangible Assets, less Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization | Identifiable Intangible Assets, less Accumulated Amortization | ||||||||||||||||||
Finite-lived intangible assets | ||||||||||||||||||||||||
Developed technology rights | $ | 16,248 | $ | (16,016 | ) | $ | 231 | $ | 16,282 | $ | (16,014 | ) | $ | 268 | ||||||||||
Licensing agreements and other | 84 | (79 | ) | 5 |
| 79 |
| (79 | ) | — | ||||||||||||||
Trademarks | 6 | (3 | ) | 3 | 6 | (3 | ) | 3 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total finite-lived intangible assets | 16,338 | (16,099 | ) | 239 | 16,367 | (16,096 | ) | 270 | ||||||||||||||||
Indefinite-lived intangible assets-Brands | 1,164 | — | 1,164 | 1,164 | — | 1,164 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Identifiable intangible assets(a) | $ | 17,502 | $ | (16,099 | ) | $ | 1,403 | $ | 17,530 | $ | (16,096 | ) | $ | 1,434 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
(a) | The decrease inIdentifiable intangible assets, less accumulated amortization from December 31, 2019 is primarily due to amortization as well as the impact of foreign exchange, partially offset by the addition of a new licensing agreement with a useful life of ten years as a result of the acquisition of Shanghai Minghui Pharmaceutical Co., Ltd. (seeNote 1A). |
Amortization
Total amortization expense for finite-lived intangible assets was $36 million in the first three months of 2020 and $39 million in the first three months of 2019.
B. Goodwill
The following table provides the components of and changes in the carrying amount ofGoodwill:
(millions of dollars) | Developed Markets | Greater China | Emerging Markets | Total | ||||||||||||
Balance, December 31, 2019 | $ | 5,883 | $ | 1,944 | $ | 883 | $ | 8,709 | ||||||||
Other(a) | (23 | ) | — | 9 | (15 | ) | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Balance, March 29, 2020 | $ | 5,859 | $ | 1,944 | $ | 892 | $ | 8,695 | ||||||||
|
|
|
|
|
|
|
|
(a) | Reflects the impact of foreign exchange. |
F-20
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Note 10. Other Current and Noncurrent Assets
A. Other Current Assets
The following table provides the components ofOther current assets:
(millions of dollars) | March 29, 2020 | December 31, 2019 | ||||||
VAT receivables | $ | 131 | $ | 148 | ||||
Prepaid expenses | 78 | 53 | ||||||
Other accounts receivable | 53 | 49 | ||||||
Related party receivable(a) | 9 | 4 | ||||||
Other | 7 | 8 | ||||||
|
|
|
| |||||
Other current assets | $ | 278 | $ | 261 | ||||
|
|
|
|
(a) | SeeNote 15. |
B. Other Noncurrent Assets
The following table provides the components ofOther noncurrent assets:
(millions of dollars) | March 29, 2020 | December 31, 2019 | ||||||
Pension plan assets, net | $ | 164 | $ | 165 | ||||
Noncurrent inventory(a) | 78 | 76 | ||||||
Spare parts inventory | 57 | 55 | ||||||
Deferred charges | 31 | 32 | ||||||
Right of use assets for operating leases | 24 | 24 | ||||||
Deposits and advances | 20 | 20 | ||||||
VAT receivables | 17 | 10 | ||||||
Other | 15 | 18 | ||||||
|
|
|
| |||||
Other noncurrent assets | $ | 407 | $ | 399 | ||||
|
|
|
|
(a) | SeeNote 8. |
F-21
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Note 11. Other Current and Noncurrent Liabilities
A. Other Current Liabilities
The following table provides the components ofOther current liabilities:
(millions of dollars) | March 29, 2020 | December 31, 2019 | ||||||
Rebate accruals(a) | $ | 609 | $ | 737 | ||||
Legal contingencies(b) | 425 | 431 | ||||||
Accrued sales returns | 191 | 200 | ||||||
VAT payable | 98 | 82 | ||||||
Restructuring accruals(c) | 95 | 153 | ||||||
U.S. Healthcare fee accruals | 64 | 48 | ||||||
Co-marketing expense accruals | 56 | 73 | ||||||
Property and other tax accruals | 49 | 16 | ||||||
Inventory related accruals | 47 | 57 | ||||||
Service accruals | 43 | 53 | ||||||
Profit share liabilities | 32 | 28 | ||||||
Utility accruals | 25 | 25 | ||||||
Trade discount accruals | 23 | 21 | ||||||
Research and development accruals | 17 | 14 | ||||||
Deferred revenue | 11 | 7 | ||||||
Advertising and promotional accruals | 9 | 13 | ||||||
Royalty accruals | 9 | 13 | ||||||
Operating lease liabilities | 8 | 8 | ||||||
Asset retirement obligations | 3 | 3 | ||||||
Chargeback accruals | 1 | 3 | ||||||
Other | 150 | 139 | ||||||
|
|
|
| |||||
Other current liabilities | $ | 1,966 | $ | 2,125 | ||||
|
|
|
|
(a) | The decrease in rebate accruals reflects the loss of exclusivity of Lyrica in the United States, with multi-source generic competition beginning in July 2019. |
(b) | SeeNote 13A. |
(c) | SeeNote 3. |
B. Other Noncurrent Liabilities
The following table provides the components ofOther noncurrent liabilities:
(millions of dollars) | March 29, 2020 | December 31, 2019 | ||||||
Accrued sales returns | $ | 216 | $ | 217 | ||||
Legal contingencies(a) | 64 | 72 | ||||||
Restructuring accruals(b) | 49 | 49 | ||||||
Asset retirement obligations | 47 | 47 | ||||||
Operating lease liabilities | 17 | 17 | ||||||
Insurance reserves | 5 | 7 | ||||||
Related party payable(c) | 1 | 1 | ||||||
Other | 21 | 16 | ||||||
|
|
|
| |||||
Other noncurrent liabilities | $ | 420 | $ | 426 | ||||
|
|
|
|
(a) | SeeNote 13A. |
(b) | SeeNote 3. |
(c) | See Note 15. |
F-22
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Note 12. Benefit Plans
The condensed combined statements of income include benefit plan expenses attributable to Upjohn, including expenses associated with defined benefit and defined contribution plans, as well as other postretirement plans, consisting primarily of retiree medical benefits. The expenses include allocations of direct expenses as well as expenses that have been deemed attributable to the Upjohn operations.
The condensed combined statements of income include the net periodic pension and postretirement costs associated with plans sponsored by Upjohn (service cost component is for the Upjohn participants only). Net periodic pension and postretirement costs other than service costs are recognized, as required, inOther (income)/deductions—net. Net periodic pension and postretirement service costs for the Upjohn participants only are recognized, as required, inCost of sales, Selling, informational and administrative expenses and Research and development expenses, as appropriate.
The condensed combined balance sheets include the pension and postretirement benefit plan assets and liabilities of only those plans or arrangements sponsored by Upjohn.Pension benefit obligations, net at March 29, 2020 include an actuarial loss of $85 million in the three months ended March 29, 2020, resulting from a remeasurement of the Upjohn sponsored pension plan in Puerto Rico, which is recorded in Other comprehensive income/(loss), before tax. There was no change in the plan’s expected rate of return on assets for full year 2020 as a result of the remeasurement. As of March 29, 2020, Upjohn is the sponsor of pension plans, primarily in Puerto Rico, Japan, Taiwan, United Arab Emirates, Italy, South Korea, Mexico, the Philippines, Greece, Thailand, China, Germany, France and Kuwait, among other countries. In 2020, there are newly formed pension plans in Mexico for participants who previously participated in plans sponsored by Pfizer. The newly formed pension plans are partially funded and have aggregate net pension liabilities of approximately $1.8 million included inPension benefit obligations, net ($1.7 million) andAccrued compensation and related items ($0.2 million) in the condensed combined balance sheet at March 29, 2020. Upjohn is the sponsor of one postretirement plan in Puerto Rico. Included in certain of the Upjohn sponsored plans are both Upjohn andnon-Upjohn Pfizer participants. The condensed combined balance sheets at March 29, 2020 and December 31, 2019 reflect the pension plan assets and pension and postretirement plan obligations associated with thenon-Upjohn Pfizer active plan participants and inactive members as follows:
• | The pension benefit obligations associated withnon-Upjohn Pfizer active plan participants included in the condensed combined balance sheets are approximately $654 million at March 29, 2020 and $667 million at December 31, 2019. The pension benefit obligations associated with inactive members in the Japan pension plan included in the condensed combined balance sheets are approximately $483 million at March 29, 2020 and $489 million at December 31, 2019. The pension benefit obligations associated with inactive members in the Puerto Rico pension plan included in the condensed combined balance sheets are approximately $689 million at March 29, 2020 and $654 million at December 31, 2019. |
• | The pension benefit plan assets associated withnon-Upjohn Pfizer active plan participants included in the condensed combined balance sheets are approximately $681 million at March 29, 2020 and $701 million at December 31, 2019. The pension benefit plan assets associated with inactive members in the Japan pension plan included in the condensed combined balance sheets are approximately $554 million at March 29, 2020 and $560 million at December 31, 2019. The pension benefit plan assets associated with inactive members in the Puerto Rico pension plan included in the condensed combined balance sheets are approximately $448 million at March 29, 2020 and $468 million at December 31, 2019. |
F-23
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
• | The postretirement benefit obligations associated withnon-Upjohn Pfizer active plan participants included in the condensed combined balance sheets are approximately $12 million at March 29, 2020 and $11 million at December 31, 2019. The postretirement benefit obligations associated with inactive members included in the condensed combined balance sheets are approximately $154 million at March 29, 2020 and $156 million at December 31, 2019. |
Many of our employees participate in benefit plans sponsored by Pfizer. The condensed combined statements of income include the service cost associated with direct Upjohn employees participating in plans sponsored by Pfizer as well as an allocation of service cost that has been deemed attributable to Upjohn operations. The condensed combined balance sheets do not include benefit plan assets and liabilities associated with Upjohn employees participating in plans that are not sponsored by Upjohn. Service costs are recognized, as required, inCost of sales, Selling, informational and administrative expenses and Research and developmentexpenses, as appropriate. The projected benefit obligation associated with direct Upjohn employees participating in plans sponsored by Pfizer that is not included in the condensed combined balance sheets but may be required by law in certain jurisdictions to transfer upon a separation of Upjohn from Pfizer was approximately $112 million at March 29, 2020. There are approximately $67 million of assets associated with these obligations at March 29, 2020.
A. Pension and Postretirement Plans
Pension expense/(income) associated with the U.S. and international locations is included in the condensed combined statements of income as follows:
• | For the three months ended March 29, 2020—approximately $13 million expense, reflecting approximately $11 million of net periodic pension expense (service cost component is for the Upjohn participants only) associated with plans sponsored by Upjohn and approximately $2 million of service cost associated with direct Upjohn employees participating in plans sponsored by Pfizer as well as an allocation of service cost that has been deemed attributable to Upjohn operations. Included in net periodic pension expense for the first three months of 2020 is a settlement charge of approximately $14 million related to lump sum payouts to certain terminated plan participants in the Upjohn sponsored pension plan in Puerto Rico (seeNote 4). |
• | For the three months ended March 31, 2019—approximately $0.2 million expense, reflecting approximately $2.6 million of net periodic pension income (service cost component is for the Upjohn participants only) associated with plans sponsored by Upjohn and approximately $2.8 million of service cost associated with direct Upjohn employees participating in plans sponsored by Pfizer as well as an allocation of service cost that has been deemed attributable to Upjohn operations. |
Postretirement expense/(income) associated with the U.S. and international locations is included in the condensed combined statements of income as follows:
• | For the three months ended March 29, 2020—approximately $1.6 million of net periodic postretirement income (service cost component is for the Upjohn participants only) primarily associated with the postretirement plan sponsored by Upjohn. |
• | For the three months ended March 31, 2019—approximately $1.9 million of net periodic postretirement income (service cost component is for the Upjohn participants only) primarily associated with the postretirement plan sponsored by Upjohn. |
F-24
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Net Periodic Benefit Costs/(Credits)––Upjohn Sponsored Plans
The following table provides the components of net periodic benefit cost/(credit) for the Upjohn sponsored pension and postretirement plans:
Three Months Ended | ||||||||||||||||
Pension Plans | Postretirement Plan | |||||||||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | March 29, 2020 | March 31, 2019 | ||||||||||||
Service cost | $ | 3 | $ | 2 | $ | 1 | $ | — | ||||||||
Interest cost | 9 | 10 | 2 | 3 | ||||||||||||
Expected return on plan assets | (18 | ) | (17 | ) | — | — | ||||||||||
Amortization of: | ||||||||||||||||
Actuarial losses | 4 | 3 | — | — | ||||||||||||
Prior service credits | (1 | ) | (1 | ) | (4 | ) | (5 | ) | ||||||||
Settlements | 14 | — | — | — | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Net periodic benefit cost/(credit) reported inIncome | $ | 11 | $ | (3 | ) | $ | (2 | ) | $ | (2 | ) | |||||
|
|
|
|
|
|
|
|
The following table provides the amounts contributed, and the amounts expected to be contributed during 2020, to the Upjohn sponsored pension and postretirement plans from general assets for the periods indicated:
(millions of dollars) | Pension Plans | Postretirement Plan | ||||||
Contributions from our general assets for the three months ended March 29, 2020 | $ | 10 | $ | 4 | ||||
Expected contributions from our general assets during 2020(a) | 54 | 18 |
(a) | Contributions expected to be made for 2020 are inclusive of amounts contributed during the three months ended March 29, 2020. The contributions from general assets include direct employer benefit payments. |
Note 13. Commitments and Contingencies
Upjohn is subject to numerous contingencies arising in the ordinary course of business, including but not limited to those discussed below. For a discussion of our tax contingencies, see Note 5B.
A. Legal Proceedings
Ournon-tax contingencies can include, but are not limited to, the following:
• | Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in many but not all of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets, and in some cases, liability where we are defendants for allegedly causing delay of generic entry. |
• | Product liability and other product-related litigation, which can include personal injury, consumer,off-label promotion, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. |
• | Commercial and other matters, which can include product-pricing claims, environmental claims and proceedings and employee litigation, can involve complexities that will vary from matter to matter. |
• | Government investigations, which can involve regulation by national, state and local government agencies in the U.S. and in other countries. |
F-25
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.
We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.
We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to a multi-district litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.
A1. Legal Proceedings––Patent Litigation
Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. Patent rights to certain of our products are being challenged in various jurisdictions throughout the world. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. We also may be involved in other proceedings, such as inter partes review, post-grant review,re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our
F-26
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
existing products. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.
Lyrica
• | Canada |
In June 2014, Pharmascience Inc. commenced an action against Pfizer Canada Inc., Warner-Lambert Company and Warner-Lambert Company LLC (the Pfizer Canada Defendants) seeking damages in connection with an earlier unsuccessful patent litigation brought by the Pfizer Canada Defendants involving pregabalin. The case is in the discovery phase and a trial date has been set for the first quarter of 2021.
• | Japan |
Sawai Pharmaceutical Company Limited (a Japanese generic company) (Sawai) filed an invalidation action against the Lyrica pain use patent in the Japanese Patent Office (JPO) in January 2017. Nissin Pharmaceutical Company Limited (Nissin) and Sandoz intervened and their arguments were considered with those of Sawai. Hexal AG has filed a separate invalidation action that has been stayed pending the result of the Sawai/Nissin case. Nippon Chemiphar and Teva have also subsequently been allowed to intervene in the case. In February 2019, the JPO issued an interim decision indicating the granted claims were potentially invalid. In July 2019, we submitted proposed claim amendments to the JPO to overcome the issues raised by the interim decision, as well as additional arguments supporting the validity of the patent. In November 2019, we received the third-party challengers’ rebuttal briefs and on February 13, 2020 we submitted our final reply brief to the JPO.
• | United Kingdom |
In June 2014, Mylan N.V. (Mylan) filed an invalidity action against the Lyrica pain use patent in the High Court. In September 2014, Actavis UK Ltd (Actavis) also filed an invalidity action in the same court. In December 2014, we filed in the High Court an infringement action against Actavis requesting preliminary relief. Our request for preliminary relief was denied in a January 2015 hearing and the denial subsequently was confirmed on appeal.
In February 2015, the National Health Service (NHS) England was ordered by the High Court, as an intermediary, to issue guidance for prescribers and pharmacists directing the prescription and dispensing of Lyrica by brand when pregabalin was prescribed for the treatment of neuropathic pain. NHS Wales and NHS Northern Ireland also issued prescribing guidance. The guidance to prescribe and dispense Lyrica for neuropathic pain was withdrawn upon patent expiration in July 2017. The Mylan and Actavis invalidity actions were heard in the High Court at the same time as the Actavis infringement action. In September 2015, the High Court ruled that (i) Actavis had not infringed the pregabalin pain patent; (ii) certain patent claims directed generally to pain and neuropathic pain were not valid; and (iii) other patent claims for other types of neuropathic pain were valid. All parties appealed.
In October 2016, the Court of Appeal dismissed all appeals and affirmed the High Court’s decision. In March 2017, the Supreme Court of the United Kingdom granted Pfizer leave to appeal the Court of Appeal’s decision, and subsequently granted the generic companies leave to appeal as well. In November 2018, the Supreme Court issued its decision finding all claims relevant to the neuropathic pain indications were invalid.
We also filed infringement actions against Teva Pharmaceuticals Industries Ltd. (Teva) and Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s) in February 2015, seeking the same relief as in the action against Actavis. Dr. Reddy’s filed invalidity counterclaims. These actions were stayed pending the outcome of the Actavis and Mylan cases.
F-27
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
In October 2015, after Sandoz launched a full label generic pregabalin product, we obtained from the High Court a preliminary injunction enjoining Sandoz from further sales of the product and ordering them to provide the identity of the parties holding the Sandoz product. After Sandoz advised that the parties were wholesaler AAH Pharmaceuticals Ltd and pharmacy chain Lloyds Pharmacy (supplied by AAH), we noticed these parties, requesting the cessation of further sales and the withdrawal of the Sandoz generic pregabalin product. In October 2015, after Lloyds was added to the Sandoz action as a respondent, we obtained a preliminary order from the High Court pursuant to which Lloyds was required to advise its pharmacists that the Sandoz generic pregabalin product should not be dispensed. In November 2015, the High Court confirmed the preliminary injunction against Sandoz and Lloyds. Upon agreement of the parties, in December 2015, the proceedings against Lloyds were terminated, and the proceedings against Sandoz were stayed pending outcome in the Actavis and Mylan cases. In December 2016, Sandoz sought to withdraw the preliminary injunction, however, in December 2016, the London High Court denied Sandoz’s request and the preliminary injunction remained in place until patent expiration in July 2017.
A2. Legal Proceedings—Product Litigation
Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.
Effexor
Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth (a subsidiary of Pfizer) and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey.
In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers andend-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court.
Lipitor
• | Antitrust Actions |
Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from
F-28
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated forpre-trial proceedings in a Multi-District Litigation (In re Lipitor Antitrust LitigationMDL-2332) in the U.S. District Court for the District of New Jersey.
In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court.
Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.
• | Personal Injury Actions |
A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages.
In February 2014, the federal actions were transferred for consolidatedpre-trial proceedings to a Multi-District Litigation (In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II)MDL-2502) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court’s decision.
Viagra
Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California (In Re: Viagra (Sildenafil Citrate) Products Liability Litigation,MDL-2691), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Eli Lilly and Company (Lilly) with respect to Cialis have also been consolidated in the Multi-District Litigation(In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation,MDL-2691). In January 2020, the District Court granted our and Lilly’s motion to exclude all of plaintiffs’ general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs’ claims.
F-29
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
A3. Legal Proceedings—Commercial and Other Matters
Contracts with Iraqi Ministry of Health
In October 2017, a number of United States service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2018, the U.S. Department of Justice requested documents related to this matter, which have been provided.
A4. Legal Proceedings—Government Investigations
Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.
Phenytoin Sodium Capsules
In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition & Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws. In December 2016, the CMA imposed a £84.2 million fine on Pfizer and Pfizer Limited.Pfizer appealed the CMA decision to The Competition Appeal Tribunal (the Tribunal) in February 2017. On June 7, 2018, the Tribunal overturned the CMA decision as well as the associated fine. The CMA appealed the judgment to the Court of Appeal. In March 2020, the Court of Appeal affirmed the Tribunal’s decision.
Greenstone Investigations
• | U.S. Department of Justice Antitrust Division Investigation |
Since July 2017, the U.S. Department of Justice’s Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.
• | State Attorneys General Generics Antitrust Litigation |
In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation (In re: Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724) in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint will be transferred to the Multi-District Litigation.
Contracts with Iraqi Ministry of Health
For information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health, seeNote 13A3.
F-30
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to or following the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of March 29, 2020, recorded amounts for the estimated fair value of these indemnifications are not significant.
Note 14. Segment, Geographic and Revenue Information
A. Segment Information
We manage our commercial operations through three distinct business segments: Developed Markets; Greater China; and Emerging Markets. The operating segments are each led by a single manager. Each operating segment has responsibility for its commercial activities.
We regularly review our segments and the approach used by management to evaluate performance and allocate resources.
Operating Segments
• | Developed Markets consists of the U.S., Canada, Europe (including Eastern Europe), Russia and other former Soviet Union countries, Turkey, Israel, Japan, South Korea, Australia, and New Zealand. |
• | Greater China consists of China, Hong Kong, Macau and Taiwan. |
• | Emerging Markets consists of Asia (excluding Greater China, Japan and South Korea), Latin America, Africa, and the Middle East. |
Our chief operating decision maker uses the revenues and earnings of the three operating segments, among other factors, for performance evaluation and resource allocation.
Other Costs and Business Activities
Certain costs are not allocated to our operating segment results, such as costs, if any, associated with the following:
• | RDM costs managed by the Upjohn R&D organization as well as costs managed by Pfizer’s R&D organization, primarily for safety and regulatory related activities. |
• | Corporate and other unallocated costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment (such as all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization) as business unit (segment) management does not manage these costs. |
• | Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain |
F-31
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to,non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. |
Segment Assets
We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $16.2 billion as of March 29, 2020 and $16.4 billion as of December 31, 2019.
Selected Income Statement Information
The following table provides selected income statement information by reportable segment:
Revenues | Earnings(a) | |||||||||||||||
Three Months Ended | Three Months Ended | |||||||||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | March 29, 2020 | March 31, 2019 | ||||||||||||
Reportable Segments: | ||||||||||||||||
Developed Markets | $ | 1,127 | $ | 2,006 | $ | 694 | $ | 1,519 | ||||||||
Greater China | 481 | 811 | 383 | 662 | ||||||||||||
Emerging Markets | 253 | 253 | 164 | 172 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Total reportable segments | 1,861 | 3,071 | 1,241 | 2,353 | ||||||||||||
Other business activities(b) | — | — | (53 | ) | (55 | ) | ||||||||||
Reconciling Items: | — | — | ||||||||||||||
Corporate and other unallocated(c) | — | — | (246 | ) | (264 | ) | ||||||||||
Purchase accounting adjustments(c) | — | — | (36 | ) | (38 | ) | ||||||||||
Certain significant items(c), (d) | — | — | (21 | ) | (6 | ) | ||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 1,861 | $ | 3,071 | $ | 885 | $ | 1,991 | |||||||||
|
|
|
|
|
|
|
|
(a) | Income before provision for taxes on income. |
(b) | Other business activities include the (i) allocation of costs managed by the Upjohn R&D organization, primarily for existing brand innovation; and (ii) allocation of costs managed by Pfizer’s R&D organization, primarily for safety and regulatory related activities. |
(c) | For a description, see the “Other Costs and Business Activities” section above. |
(d) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. |
For Earnings in the first three months of 2020, certain significant items include: (i) restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition of $19 million (of which $18 million is direct)–seeNote 3; and (ii) other charges of $2 million, which primarily includes unrealized losses on investments allocated from Pfizer of $1 million and net charges for certain legal matters of $1 million–seeNote 4.
For Earnings in the first three months of 2019, certain significant items include: (i) restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition of $15 million (of which $6 million is direct)–seeNote 3; and (ii) other income of $9 million, which primarily includes inOther (income)/deductions–net income of $6 million for a reversal of a legal accrual where a loss was no longer deemed probable net of charges for certain legal matters; net gains on investments allocated from Pfizer of $7 million; and costs associated with certain initiatives in international jurisdictions of $4 million–seeNote 4.
F-32
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
The operating segment information does not purport to represent the revenues, costs and income before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.
B. Other Revenue Information
Revenues by Major Product and by Segment
The following table provides significant revenues by major product:
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Lipitor | $ | 406 | $ | 624 | ||||
Lyrica | 345 | 1,174 | ||||||
Norvasc | 194 | 302 | ||||||
Celebrex | 155 | 176 | ||||||
Viagra | 128 | 153 | ||||||
Effexor | 78 | 77 | ||||||
Zoloft | 78 | 69 | ||||||
Xalatan/Xalacom | 61 | 62 | ||||||
Xanax | 46 | 37 | ||||||
Revatio | 18 | 44 | ||||||
Greenstone(a) | 133 | 125 | ||||||
Other | 219 | 228 | ||||||
|
|
|
| |||||
Total revenues | $ | 1,861 | $ | 3,071 | ||||
|
|
|
|
(a) | Includes revenues of approximately $52 million in the first three months of 2020 and $44 million in the first three months of 2019 associated with the sale of generic medicines under a three-year license agreement entered into with Allergan in March 2016. In October 2018, the agreement was extended through December 2021. Under the agreement, on a quarterly basis, we make a profit-sharing payment to Allergan. |
The following table provides significant revenues by major product by segment:
Three Months Ended March 29, 2020 | ||||||||||||||||
(millions of dollars) | Developed Markets | Greater China | Emerging Markets | Total | ||||||||||||
Lipitor | $ | 117 | $ | 226 | $ | 63 | $ | 406 | ||||||||
Lyrica | 299 | 16 | 30 | 345 | ||||||||||||
Norvasc | 64 | 103 | 26 | 194 | ||||||||||||
Celebrex | 93 | 39 | 23 | 155 | ||||||||||||
Viagra | 64 | 47 | 17 | 128 | ||||||||||||
Effexor | 62 | 8 | 8 | 78 | ||||||||||||
Zoloft | 41 | 21 | 17 | 78 | ||||||||||||
Xalatan/Xalacom | 49 | 2 | 11 | 61 | ||||||||||||
Xanax | 35 | 1 | 10 | 46 | ||||||||||||
Revatio | 15 | 2 | 2 | 18 | ||||||||||||
Greenstone | 133 | — | — | 133 | ||||||||||||
Other | 156 | 16 | 48 | 219 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Total revenues | $ | 1,127 | $ | 481 | $ | 253 | $ | 1,861 | ||||||||
|
|
|
|
|
|
|
|
F-33
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
The following table provides significant revenues by major product by segment:
Three Months Ended March 31, 2019 | ||||||||||||||||
(millions of dollars) | Developed Markets | Greater China | Emerging Markets | Total | ||||||||||||
Lipitor | $ | 123 | $ | 438 | $ | 62 | $ | 624 | ||||||||
Lyrica | 1,127 | 16 | 31 | 1,174 | ||||||||||||
Norvasc | 77 | 200 | 25 | 302 | ||||||||||||
Celebrex | 96 | 47 | 33 | 176 | ||||||||||||
Viagra | 83 | 54 | 16 | 153 | ||||||||||||
Effexor | 58 | 12 | 8 | 77 | ||||||||||||
Zoloft | 36 | 20 | 13 | 69 | ||||||||||||
Xalatan/Xalacom | 50 | 2 | 10 | 62 | ||||||||||||
Xanax | 25 | 1 | 11 | 37 | ||||||||||||
Revatio | 41 | 2 | 1 | 44 | ||||||||||||
Greenstone | 125 | — | — | 125 | ||||||||||||
Other | 164 | 19 | 44 | 228 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Total revenues | $ | 2,006 | $ | 811 | $ | 253 | $ | 3,071 | ||||||||
|
|
|
|
|
|
|
|
Note 15. Related Party Transactions
These condensed combined financial statements include related party transactions, such as sales to Pfizer, the costs of goods manufactured in manufacturing plants that were shared with other Pfizer business units and other operating activities between Pfizer and Upjohn.
Substantially all balances from transactions among Upjohn and Pfizer that are expected to be cash-settled, if any, are included, depending on the nature of the balance, inOther current assets, Other noncurrent assets,Other current liabilities andOther noncurrent liabilities on the condensed combined balance sheets. At March 29, 2020 and December 31, 2019, included inOther current assets are related party receivables from Pfizer of $9 million and $4 million, respectively, related to an employee secondment agreement and related intercompany lease agreement at our Tuas, Singapore manufacturing site described below (seeNote 10A). Included inOther noncurrent liabilities at March 29, 2020 and December 31, 2019 is a related party payable to Pfizer of $1 million related to a transfer agreement for certain manufacturing assets (seeNote 11B). All balances and transactions among Upjohn and Pfizer that are not cash-settled are shown as part ofBusiness unit equity on the condensed combined balance sheets, for all periods presented, and represent the net of amounts settled without payment (to)/from Pfizer. Such amounts are reflected in the condensed combined statements of cash flows based on the cash flows made by Pfizer on behalf of Upjohn, with the offset reflected in Net financing activities with Pfizer in the financing section.
Pfizer uses a centralized approach to cash management and financing its operations. During the periods covered by these condensed combined financial statements, excess cash receipts were remitted to Pfizer on a regular basis and are reflected withinBusiness unit equity in the condensed combined financial statements. Similarly, Upjohn cash disbursements were predominantly funded through Pfizer’s cash accounts and are reflected withinBusiness unit equity in the condensed combined financial statements.
Historically, Pfizer has provided significant corporate, manufacturing and shared services functions and resources to us. Our condensed combined financial statements reflect an allocation of these costs (seeNote 1B).Management believes that these allocations are a reasonable reflection of the services received. However, these allocations may not reflect the expenses that would have been incurred if we had operated as an independent standalone company during the periods presented.
F-34
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Pfizer and Viatris (seeNote 1A) will enter into certain additional agreements that will govern certain arrangements between them following the consummation of the transaction relating to, among other things, tax matters, employee matters, intellectual property matters, transition services and manufacturing and supply arrangements. Such agreements are generally expected to become effective upon the consummation of the planned combination of Upjohn and Mylan.
Intercompany Leases and Agreement with Pfizer—Effective May 27, 2019, Upjohn entered into operating leases with a subsidiary of Pfizer (lessee) to lease its manufacturing plant and equipment in Singapore to Pfizer. The leases are for five years but the lessee may terminate or extend the term upon agreement without penalty. The lease payment includes variable payments for property tax and plant insurance. The residual value of the underlying assets was calculated using the depreciation and book value included in the lease contract terms. To manage the risk of the residual assets, plant insurance is included in the lease payments.
We had the following lease income related to these operating leases with Pfizer, which is included inOther (income)/deductions—net(see Note 4):
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Buildings | $ | 4 | $ | — | ||||
Machinery and equipment | 9 | — | ||||||
|
|
|
| |||||
Total lease income from Pfizer | $ | 12 | $ | — | ||||
|
|
|
|
The carrying value associated with the leased assets was $304 million as of March 29, 2020 inclusive of accumulated depreciation of $370 million. The carrying value associated with the leased assets was $308 million as of December 31, 2019 inclusive of accumulated depreciation of $360 million.
The undiscounted cash flows we expect to receive from Pfizer under these operating leases are as follows:
(millions of dollars) | ||||
Period | Expected Undiscounted Cash Inflows | |||
Next one year(a) | $ | 45 | ||
1-2 years | 45 | |||
2-3 years | 45 | |||
3-4 years | 45 | |||
4-5 years | 11 | |||
|
| |||
Total lease payments | $ | 192 | ||
|
|
(a) | Reflects lease payments due within 12 months subsequent to the March 29, 2020 balance sheet date. |
Also, in connection with the property and equipment lease agreements in Singapore, Pfizer and Upjohn entered into an employee secondment agreement whereby certain Upjohn employees carry out the Pfizer manufacturing operations at the leased site, and in return Pfizer reimburses Upjohn for the costs, primarily salaries, of those employees (see above for the receivable due from Pfizer related to this agreement). The service agreement is for a term of five years but, subject to the terms of the agreement, can be terminated or extended upon agreement without penalty.
F-35
NOTES TO UNAUDITED CONDENSED COMBINED FINANCIAL STATEMENTS
Net Transfers—Pfizer—Net transfers (to)/from Pfizer are included withinTotal Equity.
The components ofNet transfers—Pfizeron the condensed combined statements of equity are as follows:
Three Months Ended | ||||||||
(millions of dollars) | March 29, 2020 | March 31, 2019 | ||||||
Centralized cash management(a) | $ | (1,083 | ) | $ | (1,829 | ) | ||
Pfizer cost allocations(b) | 214 | 233 | ||||||
Cash taxes paid(c) | 64 | 238 | ||||||
Defined benefit plans transferred from Pfizer(d) | (2 | ) | — | |||||
|
|
|
| |||||
Net transfers—Pfizer(e) | $ | (807 | ) | $ | (1,359 | ) | ||
|
|
|
|
(a) | Includes net cash remitted to Pfizer under Pfizer’s centralized cash management system. The Upjohn Business participates in Pfizer’s centralized cash management system and generally all excess cash is transferred to Pfizer on a daily basis. Cash disbursements for operations and/or investing activities are predominantly funded as needed by Pfizer. |
(b) | Reflects allocations of costs for certain support functions that were provided to Upjohn on a centralized basis within Pfizer (seeNote 1B). |
(c) | Includes taxes deemed paid by Pfizer on behalf of Upjohn, which were derived as if Upjohn filed a tax return separate from Pfizer in the various jurisdictions where it does business. |
(d) | Represents newly formed Upjohn defined benefit plans for participants who previously participated in defined benefit plans sponsored by Pfizer (seeNote 12). |
(e) | As presented on the condensed combined statements of equity for the three months ended March 29, 2020 and March 31, 2019. |
Note 16. Subsequent Events
Upjohn has evaluated subsequent events from the balance sheet date through June 12, 2020, the date at which the financial statements were available to be issued, and determined that there are no other items to disclose.
F-36